LRRK2 Inhibitor - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "LRRK2 inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in LRRK2 inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

LRRK2 inhibitor Understanding

LRRK2 inhibitor: Overview

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. LRRK2 is a 286 kDa complex scaffolding protein containing ankyrin, leucine-rich and WD40 repeats, and a catalytic core with Ras-Of-Complex (ROC) GTPase and serine-threonine kinase activities. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the major genetic cause of autosomal-dominantly inherited Parkinson's disease. Studies found that inhibiting the activity of LRRK2 kinase may benefit patients both with and without Parkinson disease-related mutation. Research and clinical development activities are going on toward the development of pharmacological inhibitors of LRRK2 kinase activity as a therapeutic intervention.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence LRRK2 inhibitor R&D. The therapies under development are focused on novel approaches for LRRK2 inhibitor.

LRRK2 inhibitor Emerging Drugs Chapters

This segment of the LRRK2 inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

LRRK2 inhibitor Emerging Drugs

- ION859: Ionis Pharmaceuticals

ION859 (formerly IONIS-BIIB7Rx), also known as BIIB094, is an investigational antisense medicine targeting Leucine Rich Repeat Kinase 2 (LRRK2) messenger ribonucleic acid (mRNA). It is designed to prevent the production of LRRK2 protein and is currently under Phase II clinical evaluation for Parkinson's disease (PD). It is hypothesized that reduction of LRRK2 mRNA and, subsequently, reduced synthesis of LRRK2 protein will ameliorate the toxic effects of gain-of-function mutations as well as the primary pathology in PD patients without the LRRK2 mutation.

- DNL151: Denali Therapeutics

DNL151 is a potent, selective and brain-penetrant oral small molecule inhibitor of LRRK2. It is in Phase I clinical development for Parkinson's disease. Denali Therapeutics is developing this drug in collaboration with Biogen. LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson's disease.

Further product details are provided in the report……..

LRRK2 inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different LRRK2 inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players working on LRRK2 inhibitor

There are approx. 8+ key companies which are developing the LRRK2 inhibitor. The companies which have their LRRK2 inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Ionis Pharmaceuticals.

- Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

- Late-stage products (Phase III and

- Mid-stage products (Phase II and

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

LRRK2 inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravaginal

- Oral

- Parenteral

- Subcutaneous

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

LRRK2 inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses LRRK2 inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging LRRK2 inhibitor drugs.

LRRK2 inhibitor Report Insights

- LRRK2 inhibitor Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

LRRK2 inhibitor Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing LRRK2 inhibitor drugs?

- How many LRRK2 inhibitor drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for LRRK2 inhibitor?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the LRRK2 inhibitor therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for LRRK2 inhibitor and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Ionis Pharmaceuticals

- Denali Therapeutics

- Neuron23

- Voronoi

- E-Scape Bio

Key Products

- ION859

- DNL151

- Small molecule therapeutics

- VRN-01

- ESB-5070

LRRK2 Inhibitor - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
LRRK2 inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
LRRK2 inhibitor - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• LRRK2 inhibitor companies' collaborations, Licensing, Acquisition -Deal Value Trends
LRRK2 inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
ION859: Ionis Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
DNL151: Denali Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Leucine-rich repeat kinase 2 inhibitor: Cerevel therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
LRRK2 inhibitor Key Companies
LRRK2 inhibitor Key Products
LRRK2 inhibitor- Unmet Needs
LRRK2 inhibitor- Market Drivers and Barriers
LRRK2 inhibitor- Future Perspectives and Conclusion
LRRK2 inhibitor Analyst Views
LRRK2 inhibitor Key Companies
Appendix

List of Tables

Table 1 Total Products for LRRK2 inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for LRRK2 inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Autism Spectrum Disorder Market Growth (Status and Outlook) 2021-2026
    Published: 17-Mar-2021        Price: US 3660 Onwards        Pages: 117
    According to this latest study, the 2021 growth of Autism Spectrum Disorder will have significant change from previous year. By the most conservative estimates of global Autism Spectrum Disorder market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 384400 million in 2020. Over the next five years the Autism Spectrum Disorder market will register a 17.9% CAGR in terms of revenue, the global market size will reach US$ 743920 million by 2026. ......
  • Global Gabapentin Market Growth 2021-2026
    Published: 16-Mar-2021        Price: US 3660 Onwards        Pages: 159
    According to this latest study, the 2021 growth of Gabapentin will have significant change from previous year. By the most conservative estimates of global Gabapentin market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1482.5 million in 2020. Over the next five years the Gabapentin market will register a 1.9% CAGR in terms of revenue, the global market size will reach US$ 1596.4 million by 2026. This report presents a comprehensi......
  • Global Restless Legs Syndrome Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
    Published: 16-Mar-2021        Price: US 3500 Onwards        Pages: 116
    Based on the Restless Legs Syndrome market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analy......
  • Global Gabapentin Market Research Report 2021
    Published: 17-Feb-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Capsule - Tablet Segment by Application - Epilepsy - Neuropathic Pain - Restle......
  • Global Gabapentin Market Analysis 2016-2020 and Forecast 2021-2026
    Published: 13-Feb-2021        Price: US 2980 Onwards        Pages: 85
    Snapshot Gabapentin is an anti-epileptic medication, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. The global Gabapentin market size is estimated at xxx million USD with a CAGR xx% from 2016-2020 and is expected to reach xxx Million USD in 2021 with a CAGR xx% from 2021 to 2026. The report begins from overview of Industry Chain structure, and describes industry environment, then ana......
  • Global Biopolar Disorder Therapeutics Market Research Report 2021
    Published: 10-Feb-2021        Price: US 2900 Onwards        Pages: 92
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Mood Stabilizers - Antipsychotic Drugs - Antidepressant Drugs - Others Segment by App......
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pi......
  • Chronic Traumatic Encephalopathy - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Chronic Traumatic Encephalopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic traumatic encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geogra......
  • Small Fiber Neuropathy - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Small Fiber Neuropathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Small Fiber Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs